The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
Open Access
- 20 May 2011
- journal article
- biology
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5), e19823
- https://doi.org/10.1371/journal.pone.0019823
Abstract
1-methyl-D-tryptophan (1-D-MT) is currently being used in clinical trials in patients with relapsed or refractory solid tumors with the aim of inhibiting indoleamine-2,3-dioxygenase (IDO)-mediated tumor immune escape. IDO is expressed in tumors and tumor-draining lymph nodes and degrades tryptophan (trp) to create an immunsuppressive micromilieu both by depleting trp and by accumulating immunosuppressive metabolites of the kynurenine (kyn) pathway. Here we show that proliferation of alloreactive T-cells cocultured with IDO1-positive human cancer cells paradoxically was inhibited by 1-D-MT. Surprisingly incubation with 1-D-MT increased kyn production of human cancer cells. Cell-free assays revealed that 1-D-MT did not alter IDO1 enzymatic activity. Instead, 1-D-MT induced IDO1 mRNA and protein expression through pathways involving p38 MAPK and JNK signalling. Treatment of cancer patients with 1-D-MT has transcriptional effects that may promote rather than suppress anti-tumor immune escape by increasing IDO1 in the cancer cells. These off-target effects should be carefully analyzed in the ongoing clinical trials with 1-D-MT.Keywords
This publication has 45 references indexed in Scilit:
- Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1)Stem Cells and Development, 2010
- LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-γ-independent manner by a JNK signaling pathway in primary murine microgliaBrain, Behavior, and Immunity, 2010
- Binding immunoglobulin protein‐treated peripheral blood monocyte‐derived dendritic cells are refractory to maturation and induce regulatory T‐cell developmentImmunology, 2009
- High-throughput detection and multiplex identification of cell contaminationsNucleic Acids Research, 2009
- Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodesBlood, 2009
- Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogueCytotechnology, 2007
- Indoleamine 2,3-dioxygenase and tumor-induced toleranceJCI Insight, 2007
- Diminished quality of life in patients with cancer correlates with tryptophan degradationZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006
- Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor growth inhibition induced during tumor immunotherapy with rIL-12International Immunology, 1996